-
Je něco špatně v tomto záznamu ?
Synthesis of 4-styrylpyrazoles and Evaluation of their Inhibitory Effects on Cyclin-dependent Kinases
D. Toman, R. Jorda, H. Ajani, V. Kryštof, P. Cankař
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
Grantová podpora
IGA_PRF_2021_024
Internal Grant Agency of Palacký University
21-06553S
Czech Science Foundation
- MeSH
- antitumorózní látky * chemie MeSH
- buněčný cyklus MeSH
- cyklin-dependentní kinasy metabolismus farmakologie MeSH
- fosforylace MeSH
- inhibitory proteinkinas chemie MeSH
- lidé MeSH
- nádory * farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Cycle-regulating and transcriptional cyclin-dependent kinases (CDKs) are attractive targets in cancer drug development. Several CDK inhibitors have already been obtained or are close to regulatory approval for clinical applications. OBJECTIVE: Phenylazopyrazole CAN508 has been described as the first selective CDK9 inhibitor with an IC50 of 350 nM. Since the azo-moiety is not a suitable functionality for drugs due to pharmacological reasons, the preparation of carbo-analogues of CAN508 with similar biological activities is desirable. The present work is focused on the synthesis of carbo-analogues similar to CAN508 and their CDK inhibition activity. METHODS: Herein, the synthesis of 21 novel carbo analogues of CAN508 and their intermediates is reported. Subsequently, target compounds 8a - 8u were evaluated for protein kinase inhibition (CDK2/cyclin E, CDK4/cyclin D, CDK9/cyclin T) and antiproliferative activities in cell lines (K562, MCF-7, MV4-11). Moreover, the binding mode of derivative 8s in the active site of CDK9 was modelled. RESULTS: Compounds 8a - 8u were obtained from key intermediate 7, which was prepared by linear synthesis involving Vilsmeier-Haack, Knoevenagel, Hunsdiecker, and Suzuki-Miyaura reactions. Styrylpyrazoles 8t and 8u were the most potent CDK9 inhibitors with IC50 values of approximately 1 μM. Molecular modelling suggested binding in the active site of CDK9. The flow cytometric analysis of MV4-11 cells treated with the most active styrylpyrazoles showed a significant G1-arrest. CONCLUSION: The prepared styrylpyrazoles showed inhibition activity towards CDKs and can provide a novel chemotype of kinase inhibitors.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019559
- 003
- CZ-PrNML
- 005
- 20220804135756.0
- 007
- ta
- 008
- 220720s2022 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1573406417666210806095710 $2 doi
- 035 __
- $a (PubMed)34365958
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Toman, Daniel $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic
- 245 10
- $a Synthesis of 4-styrylpyrazoles and Evaluation of their Inhibitory Effects on Cyclin-dependent Kinases / $c D. Toman, R. Jorda, H. Ajani, V. Kryštof, P. Cankař
- 520 9_
- $a BACKGROUND: Cycle-regulating and transcriptional cyclin-dependent kinases (CDKs) are attractive targets in cancer drug development. Several CDK inhibitors have already been obtained or are close to regulatory approval for clinical applications. OBJECTIVE: Phenylazopyrazole CAN508 has been described as the first selective CDK9 inhibitor with an IC50 of 350 nM. Since the azo-moiety is not a suitable functionality for drugs due to pharmacological reasons, the preparation of carbo-analogues of CAN508 with similar biological activities is desirable. The present work is focused on the synthesis of carbo-analogues similar to CAN508 and their CDK inhibition activity. METHODS: Herein, the synthesis of 21 novel carbo analogues of CAN508 and their intermediates is reported. Subsequently, target compounds 8a - 8u were evaluated for protein kinase inhibition (CDK2/cyclin E, CDK4/cyclin D, CDK9/cyclin T) and antiproliferative activities in cell lines (K562, MCF-7, MV4-11). Moreover, the binding mode of derivative 8s in the active site of CDK9 was modelled. RESULTS: Compounds 8a - 8u were obtained from key intermediate 7, which was prepared by linear synthesis involving Vilsmeier-Haack, Knoevenagel, Hunsdiecker, and Suzuki-Miyaura reactions. Styrylpyrazoles 8t and 8u were the most potent CDK9 inhibitors with IC50 values of approximately 1 μM. Molecular modelling suggested binding in the active site of CDK9. The flow cytometric analysis of MV4-11 cells treated with the most active styrylpyrazoles showed a significant G1-arrest. CONCLUSION: The prepared styrylpyrazoles showed inhibition activity towards CDKs and can provide a novel chemotype of kinase inhibitors.
- 650 12
- $a antitumorózní látky $x chemie $7 D000970
- 650 _2
- $a buněčný cyklus $7 D002453
- 650 _2
- $a cyklin-dependentní kinasy $x metabolismus $x farmakologie $7 D018844
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory $x farmakoterapie $7 D009369
- 650 _2
- $a fosforylace $7 D010766
- 650 _2
- $a inhibitory proteinkinas $x chemie $7 D047428
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jorda, Radek $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic
- 700 1_
- $a Ajani, Haresh $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nam. 2, 166 10 Prague 6, Czech Republic
- 700 1_
- $a Kryštof, Vladimír $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic
- 700 1_
- $a Cankař, Petr $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic
- 773 0_
- $w MED00180387 $t Medicinal chemistry (Shariqah (United Arab Emirates)) $x 1875-6638 $g Roč. 18, č. 4 (2022), s. 484-496
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34365958 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135749 $b ABA008
- 999 __
- $a ok $b bmc $g 1822959 $s 1170802
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 18 $c 4 $d 484-496 $e - $i 1875-6638 $m Medicinal chemistry $n Med Chem $x MED00180387
- GRA __
- $a IGA_PRF_2021_024 $p Internal Grant Agency of Palacký University
- GRA __
- $a 21-06553S $p Czech Science Foundation
- LZP __
- $a Pubmed-20220720